GLP1R and heart failure: A post-hoc analysis by Neves et al. [12] demonstrated that GLP-1 RA therapy significantly reduced the risk of MACE (HR: 0.77) and heart failure hospitalisation (HR: 0.72) compared to placebo in patients not taking background SGLT2i.